The relation of a cerebrospinal fluid profile associated with Alzheimer's disease with cognitive function and neuropsychiatric symptoms in sporadic cerebral amyloid angiopathy.

Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 101511643 Publication Model: Electronic Cited Medium: Internet ISSN: 1758-9193 (Electronic) NLM ISO Abbreviation: Alzheimers Res Ther Subsets: MEDLINE

Original Publication: [London] : BioMed Central Ltd.

Alzheimer Disease*/cerebrospinal fluid ; Alzheimer Disease*/complications ; Alzheimer Disease*/diagnostic imaging ; Cerebral Amyloid Angiopathy*/cerebrospinal fluid ; Cerebral Amyloid Angiopathy*/complications ; Cerebral Amyloid Angiopathy*/diagnostic imaging ; Amyloid beta-Peptides*/cerebrospinal fluid ; Biomarkers*/cerebrospinal fluid ; tau Proteins*/cerebrospinal fluid ; Neuropsychological Tests*; Humans ; Female ; Male ; Aged ; Cross-Sectional Studies ; Cognitive Dysfunction/cerebrospinal fluid ; Cognitive Dysfunction/etiology ; Peptide Fragments/cerebrospinal fluid ; Cognition/physiology ; Middle Aged ; Magnetic Resonance Imaging

Background: Patients with sporadic cerebral amyloid angiopathy (sCAA) frequently report cognitive or neuropsychiatric symptoms. The aim of this study is to investigate whether in patients with sCAA, cognitive impairment and neuropsychiatric symptoms are associated with a cerebrospinal fluid (CSF) biomarker profile associated with Alzheimer's disease (AD).
Methods: In this cross-sectional study, we included participants with sCAA and dementia- and stroke-free, age- and sex-matched controls, who underwent a lumbar puncture, brain MRI, cognitive assessments, and self-administered and informant-based-questionnaires on neuropsychiatric symptoms. CSF phosphorylated tau, total tau and Aβ42 levels were used to divide sCAA patients in two groups: CAA with (CAA-AD+) or without a CSF biomarker profile associated with AD (CAA-AD-). Performance on global cognition, specific cognitive domains (episodic memory, working memory, processing speed, verbal fluency, visuoconstruction, and executive functioning), presence and severity of neuropsychiatric symptoms, were compared between groups.
Results: sCAA-AD+ (n=31; mean age: 72 ± 6; 42%, 61% female) and sCAA-AD- (n=23; 70 ± 5; 42% female) participants did not differ with respect to global cognition or type of affected cognitive domain(s). The number or severity of neuropsychiatric symptoms also did not differ between sCAA-AD+ and sCAA-AD- participants. These results did not change after exclusion of patients without prior ICH.
Conclusions: In participants with sCAA, a CSF biomarker profile associated with AD does not impact global cognition or specific cognitive domains, or the presence of neuropsychiatric symptoms.
(© 2024. The Author(s).)

Neurology. 2019 Apr 2;92(14):e1567-e1579. (PMID: 30842300)
Stroke. 2016 Aug;47(8):2010-6. (PMID: 27338926)
JAMA Psychiatry. 2022 Apr 01;79(4):359-367. (PMID: 35171235)
AJR Am J Roentgenol. 1987 Aug;149(2):351-6. (PMID: 3496763)
Stroke. 2022 Feb;53(2):552-557. (PMID: 34538086)
J Nucl Med. 2009 Dec;50(12):1969-74. (PMID: 19910418)
Neurology. 2015 Dec 1;85(22):1930-6. (PMID: 26537052)
Neuroimage. 2021 Aug 15;237:118175. (PMID: 34000407)
Front Psychol. 2016 Oct 20;7:1601. (PMID: 27812340)
J Geriatr Psychiatry Neurol. 2009 Jun;22(2):103-9. (PMID: 19417219)
Ageing Res Rev. 2015 Nov;24(Pt B):232-62. (PMID: 26318058)
Alzheimers Dement (Amst). 2021 Apr 01;13(1):e12031. (PMID: 33816750)
Neuroimage. 2016 Dec;143:235-249. (PMID: 27612647)
J Alzheimers Dis. 2016 Mar 8;52(1):171-8. (PMID: 27060947)
Alzheimers Dement. 2018 Apr;14(4):535-562. (PMID: 29653606)
Lancet Neurol. 2013 Aug;12(8):822-38. (PMID: 23867200)
J Neuropsychiatry Clin Neurosci. 1992 Spring;4(2):134-9. (PMID: 1627973)
Neurology. 2018 May 15;90(20):e1751-e1758. (PMID: 29678935)
Alzheimers Dement (N Y). 2021 Feb 14;7(1):e12132. (PMID: 33614897)
Ann Neurol. 2023 Jun;93(6):1173-1186. (PMID: 36707720)
EMBO Mol Med. 2016 Jun 01;8(6):595-608. (PMID: 27025652)
J Alzheimers Dis. 2022;87(2):791-802. (PMID: 35367960)
JAMA Neurol. 2016 Aug 1;73(8):994-1001. (PMID: 27366898)
Neurology. 2021 Apr 13;96(15):e1975-e1986. (PMID: 33627498)
Alzheimers Dement. 2023 Oct;19(10):4498-4506. (PMID: 35142047)
J Alzheimers Dis. 2015;47(2):421-32. (PMID: 26401564)
Neurology. 2010 Apr 27;74(17):1346-50. (PMID: 20421578)
Neurology. 1994 Dec;44(12):2308-14. (PMID: 7991117)
J Am Geriatr Soc. 2005 Apr;53(4):695-9. (PMID: 15817019)
Brain. 2015 Jan;138(Pt 1):179-88. (PMID: 25367025)
Neurology. 2009 Nov 24;73(21):1759-66. (PMID: 19933977)
Neurology. 2020 Jul 7;95(1):e46-e58. (PMID: 32522798)
Stroke. 2022 Jun;53(6):1944-1953. (PMID: 35264008)
J Neurol Neurosurg Psychiatry. 2022 Mar;93(3):232-237. (PMID: 34728587)
Hum Brain Mapp. 2017 Jul;38(7):3723-3731. (PMID: 28462514)
Neurobiol Aging. 2015 Oct;36(10):2702-8. (PMID: 26239176)
J Am Heart Assoc. 2021 Nov 16;10(22):e022089. (PMID: 34755541)
Curr Opin Neurol. 2018 Feb;31(1):28-35. (PMID: 29120920)
Alzheimers Dement. 2022 Jan;18(1):10-28. (PMID: 34057813)
J Alzheimers Dis. 2011;25(1):163-73. (PMID: 21368379)
Alzheimers Res Ther. 2021 Apr 20;13(1):84. (PMID: 33879243)
J Clin Exp Neuropsychol. 2012;34(6):598-605. (PMID: 22384819)
J Clin Med. 2022 Jul 13;11(14):. (PMID: 35887823)
J Neuropsychiatry Clin Neurosci. 2000 Spring;12(2):233-9. (PMID: 11001602)

733050822 Netherlands ZONMW_ ZonMw; 733050822 Netherlands ZONMW_ ZonMw; 733050822 Netherlands ZONMW_ ZonMw; 5R01NS104147-02 United States NH NIH HHS

0 (Amyloid beta-Peptides)
0 (Biomarkers)
0 (tau Proteins)
0 (Peptide Fragments)
0 (amyloid beta-protein (1-42))

Date Created: 20240504 Date Completed: 20240504 Latest Revision: 20240712

20240712

PMC11069247

10.1186/s13195-024-01454-3

38704569